SCHEMBL28777

SCHEMBL28777

CON(C)C(=O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.54
TSHR P16473 2/20 0.50
HSD11B1 P28845 1/20 0.48
HPGD P15428 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
RAB9A P51151 2/20 0.44
CES2 O00748 2/20 0.44
CES1 P23141 2/20 0.44
NPC1 O15118 1/20 0.44
KMT2A Q03164 3/20 0.43
F2 P00734 1/20 0.43
LMNA P02545 1/20 0.43
RECQL P46063 1/20 0.42
DAO P14920 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
PDE4D Q08499 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7476159 0.98 MLYCD (0.53) MLYCDTSHRHSD11B1HPGDKDM4E
SCHEMBL3303829 0.92 HPGD (0.56) MLYCDHPGDALDH1A1RAB9ANPC1
SCHEMBL4449884 0.88 MAPT (0.56) MLYCDHPGDKDM4EALDH1A1RAB9A
SCHEMBL8988273 0.86 MLYCD (0.44) MLYCDTSHRHSD11B1ALDH1A1RAB9A
SCHEMBL19533698 0.85 SMN1; SMN2 (0.59) MLYCDHPGDKDM4EALDH1A1RAB9A
SCHEMBL22531823 0.85 MLYCD (0.57) MLYCDTSHRHPGDKDM4EALDH1A1
SCHEMBL15281239 0.85 KMT2A (0.50) MLYCDTSHRHPGDCES2CES1
SCHEMBL772236 0.84 KMO (0.53) TSHRHPGDKMT2ALMNAMEN1
SCHEMBL6492606 0.84 ATM (0.60) HPGDKDM4EALDH1A1RAB9ANPC1
SCHEMBL24512661 0.82 MLYCD (0.48) MLYCDHPGDKDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 758 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109670-A1 METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE Shanghai OuChem Bio-Technology Co., LTD (CN) 2026-04-23 US claimed
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 US claimed
CN-119059958-A Method for aryl debromination acylation of bromobenzazepine compounds 上海沃凯生物技术有限公司 2024-12-03 CN claimed
CN-114031487-B Synthesis method of 2-aryl acetophenone compound 南京工业大学 2024-03-15 CN claimed
CN-114751882-B Synthesis method of benzofuran 南京工业大学 2024-02-23 CN claimed
CN-114751882-A Synthetic method of benzofuran 南京工业大学 2022-07-15 CN claimed
CN-114031487-A Synthetic method of 2-aryl acetophenone compound 南京工业大学 2022-02-11 CN claimed
US-10016448-B2 Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity MERCK PATENT GMBH (DE) 2018-07-10 US claimed
US-9732032-B2 3-aminocyclopentane carboxamide derivatives MERCK PATENT GMBH (DE) 2017-08-15 US claimed
US-20170136048-A1 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY MERCK PATENT GMBH (DE) 2017-05-18 US claimed
US-20160264517-A1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-15 US claimed
EP-0476658-B1 1-Phenyl-3-phenyl-2-propyne-1-ones MERRELL DOW PHARMA (US) 1995-11-15 EP claimed
EP-0476658-A1 1-Phenyl-3-phenyl-2-propyne-1-ones MERRELL DOW PHARMACEUTICALS INC. (US) 1992-03-25 EP claimed
US-4617401-A ANTISPASMODIC AGENTS, VASODILATORS SUNTORY LTD. (JP) 1986-10-14 US claimed
EP-0039903-B1 8-SUBSTITUTED PYRROLIZIDINES AND QUATERNARY AMMONIUM SALTS THEREOF SUNTORY KABUSHIKI KAISHA (JP) 1986-04-09 EP claimed
EP-0039903-A2 8-Substituted pyrrolizidines and quaternary ammonium salts thereof SUNTORY KABUSHIKI KAISHA (JP) 1981-11-18 EP claimed
CN-122010881-A Synthesis method of 3-phenoxy-2-arylbenzofuran compound 南京工业大学 2026-05-12 CN disclosed
CN-122029158-A EGFR inhibitors 缆图药品公司 2026-05-12 CN disclosed
US-4195090-A ADRENERGIC BLOCKING AGENTS CIBA-GEIGY CORPORATION (US) 1980-03-25 US disclosed
US-4115575-A CARDIOVASCULAR DISORDERS CIBA-GEIGY CORPORATION (US) 1978-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264517-A1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES FADS1, FASN, FFAR3 MLYCD 1838/4885TSHR 2515/4885HSD11B1 1606/4885
US-10016448-B2 Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity BTK, SYK, LCK MLYCD 4583/4885TSHR 1964/4885HSD11B1 4146/4885
US-20260109670-A1 METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE NAT1, AADAC, NAA15 MLYCD 4107/4885TSHR 1863/4885HSD11B1 259/4885
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 MLYCD 1627/4885TSHR 3916/4885HSD11B1 2361/4885
US-20170136048-A1 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY BTK, SYK, LCK MLYCD 4583/4885TSHR 1964/4885HSD11B1 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.